Charles Schwab Investment Management Inc. grew its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) by 10.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,047,573 shares of the life sciences company's stock after buying an additional 103,291 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 1.36% of Integra LifeSciences worth $23,759,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. KBC Group NV lifted its position in Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company's stock worth $52,000 after buying an additional 1,120 shares in the last quarter. Nisa Investment Advisors LLC raised its holdings in shares of Integra LifeSciences by 599.6% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company's stock valued at $74,000 after purchasing an additional 2,800 shares during the period. Empowered Funds LLC bought a new stake in shares of Integra LifeSciences in the 4th quarter valued at about $180,000. Romano Brothers AND Company bought a new stake in shares of Integra LifeSciences in the 4th quarter valued at about $204,000. Finally, Mitsubishi UFJ Asset Management UK Ltd. bought a new stake in shares of Integra LifeSciences in the 4th quarter valued at about $204,000. 84.78% of the stock is owned by institutional investors.
Wall Street Analyst Weigh In
Separately, Morgan Stanley began coverage on shares of Integra LifeSciences in a report on Monday, December 2nd. They issued an "underweight" rating and a $20.00 target price on the stock. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $23.00.
Get Our Latest Analysis on Integra LifeSciences
Integra LifeSciences Stock Performance
Integra LifeSciences stock traded down $0.22 during trading hours on Friday, hitting $22.49. The company had a trading volume of 1,115,762 shares, compared to its average volume of 1,006,261. The firm has a market cap of $1.74 billion, a PE ratio of -249.86, a PEG ratio of 0.73 and a beta of 1.23. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences Holdings Co. has a one year low of $16.81 and a one year high of $35.49. The firm has a 50-day moving average of $23.85 and a 200 day moving average of $22.03.
Integra LifeSciences (NASDAQ:IART - Get Free Report) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The firm had revenue of $442.65 million for the quarter, compared to analysts' expectations of $445.15 million. During the same period in the prior year, the firm earned $0.89 EPS. The business's revenue was up 11.5% on a year-over-year basis. On average, sell-side analysts expect that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current year.
Integra LifeSciences Company Profile
(
Free Report)
Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.
Featured Articles
Before you consider Integra LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Integra LifeSciences wasn't on the list.
While Integra LifeSciences currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
